- Home
- QURE vs IMTX Comparison
QURE vs IMTX Comparison
Compare QURE & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- IMTX
- Stock Information
- Founded
- QURE 1998
- IMTX N/A
- Country
- QURE Netherlands
- IMTX Germany
- Employees
- QURE N/A
- IMTX N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QURE Health Care
- IMTX Health Care
- Exchange
- QURE Nasdaq
- IMTX Nasdaq
- Market Cap
- QURE 866.3M
- IMTX 865.5M
- IPO Year
- QURE 2007
- IMTX N/A
- Fundamental
- Price
- QURE $70.00
- IMTX $10.36
- Analyst Decision
- QURE Strong Buy
- IMTX Strong Buy
- Analyst Count
- QURE 12
- IMTX 4
- Target Price
- QURE $69.67
- IMTX $13.67
- AVG Volume (30 Days)
- QURE 2.6M
- IMTX 1.1M
- Earning Date
- QURE 10-29-2025
- IMTX 11-17-2025
- Dividend Yield
- QURE N/A
- IMTX N/A
- EPS Growth
- QURE N/A
- IMTX N/A
- EPS
- QURE N/A
- IMTX N/A
- Revenue
- QURE $14,337,000.00
- IMTX $152,823,253.00
- Revenue This Year
- QURE N/A
- IMTX N/A
- Revenue Next Year
- QURE $229.18
- IMTX $13.53
- P/E Ratio
- QURE N/A
- IMTX N/A
- Revenue Growth
- QURE N/A
- IMTX 83.61
- 52 Week Low
- QURE $5.35
- IMTX $3.30
- 52 Week High
- QURE $71.50
- IMTX $11.25
- Technical
- Relative Strength Index (RSI)
- QURE 71.31
- IMTX 61.31
- Support Level
- QURE $58.05
- IMTX $9.99
- Resistance Level
- QURE $64.75
- IMTX $10.87
- Average True Range (ATR)
- QURE 4.18
- IMTX 0.62
- MACD
- QURE -0.71
- IMTX -0.12
- Stochastic Oscillator
- QURE 89.18
- IMTX 41.94
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.